Featuring a completely updated agenda, this year’s conference will hone in on the key areas highlighted by the U.S. DOJ as high risk exposure areas for investigation, including:
• Foreign clinical research, including CROs, HCPs, R&D & other manufacturing operations
• Drug and device approvals in emerging markets
• Sales & marketing and CME activity
• Foreign subsidiary operations
Don’t miss out on this opportunity to benchmark and network with your peers as you gain best practices for revising and updating your global compliance program in light of new government enforcement initiatives.
New for this year - Interactive Working Sessions on:
A - Life Sciences Compliance Strategies for Addressing Gifts, Hospitality and Entertainment in High Risk Markets: A Practical Guide to Understanding What You Can and Cannot Do
B – Vetting Third Parties: How to Define and Execute Systematic, Risk-Based Third Party Due Diligence for Global Life Sciences Operations
Register now at http://www.americanconference.com/
# # #
About ACI: A unique organization, American Conference Institute is devoted to providing the business intelligence that senior decision-makers need to respond to challenges both here in the US, and around the world.
Visit us at http://www.americanconference.com or on our blog at http://www.americanconference.com/